All tests were performed by ENT physicians. Testing was performed on nasopharyngeal and oropharyngeal mucosa by swab sampling. Oropharyngeal testing was performed by sampling at least one tonsil and the posterior oropharyngeal wall [21]. Nasopharyngeal testing was performed unilaterally by inserting the swab via the nasal cavity, at least 2/3 into the nasopharynx, and simultaneously rotating on retraction. Both swabs were transported in the same tube and medium (Copan UTM or similar) and analyzed at the Department of Clinical Microbiology, Rigshospitalet. SARS-CoV-2-RNA were detected either by the Cobas[®] SARS-CoV-2 real-time RT-PCR test on the Cobas 6800 system (Roche, Switzerland) or using the RealStar® SARS-CoV-2 RT-PCR Kit (Altona, Germany). In brief: The nucleic acids in the patient sample were extracted together with an internal RNA control, using magnetic silica particles, and transferred to a specific RT-PCR, targeting two separate gene segments.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.